Janus Henderson Group PLC Acquires New Stake in MBX Biosciences, Inc. $MBX

Janus Henderson Group PLC bought a new position in MBX Biosciences, Inc. (NASDAQ:MBX) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,300 shares of the company’s stock, valued at approximately $308,000.

A number of other institutional investors have also recently modified their holdings of MBX. Geode Capital Management LLC increased its holdings in shares of MBX Biosciences by 27.0% during the second quarter. Geode Capital Management LLC now owns 348,447 shares of the company’s stock valued at $3,976,000 after acquiring an additional 73,989 shares in the last quarter. Rhumbline Advisers boosted its stake in MBX Biosciences by 171.6% in the 2nd quarter. Rhumbline Advisers now owns 23,662 shares of the company’s stock worth $270,000 after purchasing an additional 14,950 shares in the last quarter. XTX Topco Ltd purchased a new stake in MBX Biosciences during the 2nd quarter valued at about $135,000. The Manufacturers Life Insurance Company grew its position in MBX Biosciences by 73.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 87,097 shares of the company’s stock valued at $994,000 after purchasing an additional 36,987 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MBX Biosciences by 40.3% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company’s stock valued at $106,000 after purchasing an additional 2,682 shares in the last quarter.

Analyst Ratings Changes

MBX has been the topic of several analyst reports. Mizuho upped their target price on shares of MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Wall Street Zen lowered shares of MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Truist Financial upped their price objective on MBX Biosciences from $70.00 to $88.00 and gave the company a “buy” rating in a research report on Monday. UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of MBX Biosciences in a research note on Thursday, July 23rd. Finally, Citigroup restated an “outperform” rating on shares of MBX Biosciences in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, MBX Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $75.62.

MBX Biosciences Stock Down 0.2%

Shares of MBX stock opened at $66.01 on Wednesday. The company has a 50 day moving average price of $53.62 and a 200-day moving average price of $40.36. MBX Biosciences, Inc. has a 52 week low of $9.63 and a 52 week high of $72.64. The firm has a market capitalization of $3.18 billion, a PE ratio of -27.39 and a beta of 0.10.

MBX Biosciences (NASDAQ:MBX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10). Analysts anticipate that MBX Biosciences, Inc. will post -2.87 earnings per share for the current year.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.